Weight Loss Medications Guide 2026: GLP-1, Costs, Results

Weight-loss medication is a prescription decision, not a product page. The drugs in current use act on appetite and, for some people, on blood sugar. A clinician decides whether one of them belongs in the plan after looking at the diagnosis, the other medicines already in use, and the reasons a particular drug would be unsafe.

What these medications do

The medicines people ask about most are in the GLP-1 family, or they act on GLP-1 and a second hormone, GIP. They are taken on a schedule the label sets, usually a weekly injection, and the dose starts low so the stomach can adjust. They are not a substitute for a diet that a person can keep, and they are not a reason to skip treatment of diabetes, high blood pressure, or sleep apnea when those are already present.

Older oral medicines for weight are still used in some patients. A clinician reaches for them when a GLP-1 medicine is the wrong fit, is not covered, or is not tolerated. The choice is among real options for that person, not a ranking published for everyone.

Names that get mixed together

Semaglutide and tirzepatide are different molecules. Each one is sold under more than one brand, and the brand depends on the condition the Food and Drug Administration approved that product to treat. A diabetes brand and a weight-management brand can share an active ingredient and still differ in dose, pen, and whether a plan will pay.

• Semaglutide is the ingredient in Ozempic, which is approved for type 2 diabetes, and in Wegovy, which is approved for chronic weight management.
• Tirzepatide is the ingredient in Mounjaro, approved for type 2 diabetes, and in Zepbound, approved for chronic weight management.
• Compounded semaglutide is not either of those approved products. It is covered in the compounded semaglutide guide.

A comparison of the two molecules is in Mounjaro and Ozempic. How an online Ozempic visit actually proceeds is in how to get Ozempic prescribed online.

Who a clinician considers

The weight-management labels for these drugs are written for adults with a body mass index at or above 30, or at or above 27 when a weight-related condition is already present. Those numbers are a starting rule on the label, not a promise that everyone above the line is prescribed and everyone below it is refused. Type 2 diabetes is a separate reason a diabetes-labeled product may be considered, including for people whose weight is not the main problem.

The same visit looks for reasons not to prescribe. A personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2, is a reason these drugs are avoided. Pregnancy, a history of pancreatitis, severe stomach disease, and medicines that do not mix with the new drug are part of the same review. The clinician also asks what has already been tried with food, activity, and earlier medicines.

What the visit covers

The intake asks for the medicine list, allergies, prior weight-loss treatment, and the conditions that change the choice: diabetes, gallbladder disease, kidney disease, mood history, and any plan for pregnancy. The visit itself is a review of that history, a decision about whether labs are needed, and a plain explanation of how the dose will change if the drug is started.

If a prescription is written, it goes to a pharmacy the patient can actually use. Follow-up is part of the prescription. The dose is not left at the starting strength forever, and side effects are not left for the patient to sort out alone. The usual shape of those first months is in how long weight loss takes on Ozempic.

Side effects

Nausea, vomiting, diarrhea, constipation, and a smaller appetite are the effects people report most often, especially while the dose is going up. Eating smaller meals and reporting symptoms that do not ease is the practical response, not doubling the dose to push past them. Severe abdominal pain, signs of an allergic reaction, and symptoms of low blood sugar in someone who also takes insulin or a sulfonylurea need a clinician the same day.

A longer account of living with these effects is in GLP-1 side effects.

Cost

Price depends on which brand was prescribed, whether the plan covers that brand for that diagnosis, and which pharmacy fills it. Coverage for type 2 diabetes and coverage for weight management are often different benefits. A manufacturer savings offer, when one exists, has its own rules and does not apply to every patient. No page can quote a price that will be true at the pharmacy counter. The questions that do change the bill are in what semaglutide costs.

Treatment options that are not in this drug class are a separate conversation, and they are listed on the GLP-1 treatment page and the non-GLP-1 alternatives page.

What this article does not do

This page explains the decision. It does not approve a medication, set a dose, or replace a clinician who can see the rest of the history. Seek in-person or emergency care for severe or rapidly worsening symptoms.

Who this is for in Maryland

The patients this page is for live in Baltimore, the Washington suburbs, and the Eastern Shore.

This article is for those patients when they are deciding whether weight-loss medication fits a visit with MarylandDoc.

How the MarylandDoc visit applies

The MarylandDoc visit for this topic starts with a structured intake covering symptoms, medications, allergies, and prior treatment response. A Maryland-licensed physician (MD) reviews whether weight-loss medication is appropriate, whether labs are required, and whether another approach is safer. If a prescription is indicated, it is sent to a pharmacy the patient can use in Maryland. That prescription is not a referral to a District of Columbia or Northern Virginia clinic.

Local access

A patient in Baltimore, the Washington suburbs, and the Eastern Shore should compare weight-loss medication with care already available through Johns Hopkins Medicine or the University of Maryland Medical System, not with a District of Columbia or Northern Virginia clinic. Labs, when needed, can be drawn through a local partner in Maryland.